Silo Pharma, Inc.
SILOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Silo Pharma, Inc. (SILO) is listed under Biotechnology. At a $5.3M market cap, Silo Pharma, Inc. ranks as a micro-cap company within healthcare. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
Market Cap
$5.3M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-6.73
EPS (TTM)
$-5.79
EPS (Fwd)
$-0.70
ROE
-99.9%
ROA
-46.3%
Cash
$6.0M
Total Debt
$0
Free CF
-$2.7M
52W Change
-50.3%
Annual Financials
Cash vs Debt
Where SILO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SILO finished 12.01% below its 150-day moving average ($5.83) and 20.09% below its 200-day moving average ($6.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SILO overbought or oversold?
At the July 15, 2026 close, SILO's RSI(14) was 41.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Silo Pharma, Inc. reports $6.0M in cash and $0 in total debt. Free cash flow is running at -$2.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -99.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $72K (2022) to $72K (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Silo Pharma, Inc.'s trajectory.